By Free Republic | Created at 2024-09-21 23:04:45 | Updated at 2024-09-30 05:33:31
1 week ago
Novel treatment regimen yields promising response in advanced-phase chronic myeloid leukemia (80% remission)
Medical Xpress / University of Texas M. D. Anderson Cancer Center / The Lancet Haematology ^ | Sept. 18, 2024 | Nicholas J Short et al
Posted on 09/21/2024 3:59:08 PM PDT by ConservativeMind
According to researchers, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML)—including both accelerated or myeloid blast phases of the disease—or Philadelphia chromosome-positive acute myeloid leukemia (AML) achieved a bone marrow remission when treated with a novel combination of decitabine, venetoclax and ponatinib.
Findings from the Phase II clinical trial represent an important step forward for patients with advanced-phase CML, who tend to have poor outcomes.
"Over the last decade, there have been very few studies that evaluated a regimen to treat this rare disease and identify a potential standard-of-care treatment," said Nicholas Short, M.D.
"It is important that we get these patients into a state of marrow remission as this will allow them to be considered for a stem cell transplant. We were able to achieve this response in 80% of patients on this trial."
A total of 20 patients were enrolled in the trial, with 14 having myeloid blast-phase CML, four with accelerated-phase CML, and two with Philadelphia chromosome-positive AML.
Overall, 50% of patients achieved a complete remission or complete remission with an incomplete hematological recovery, and an additional 30% of patients achieved a morphologic leukemia-free state. Responses were seen even in patients who had received multiple prior therapies and in those with high-risk cytogenetic or molecular features.
"We were able to build on previous research, which identified synergy between the BCL-2 inhibitor, venetoclax and the BCR::ABL1 tyrosine kinase inhibitor, ponatinib," Short said.
The researchers observed expected side effects, which were consistent with previous studies with the drugs. Common side effects include neutropenia, rash and nausea.
The trial is ongoing and enrolling additional patients. MD Anderson researchers are also conducting additional studies building on the approach of adding targeted therapies into new combinations for patients with advanced-phase CML.
(Excerpt) Read more at medicalxpress.com ...
TOPICS: Health/Medicine
KEYWORDS:
Click here: to donate by Credit Card
Or here: to donate by PayPal
Or by mail to: Free Republic, LLC - PO Box 9771 - Fresno, CA 93794
Thank you very much and God bless you.
These are available today, but M.D. Anderson is still enrolling patients in the ongoing trial.
50% had complete remission or complete without full blood recovery, while 30% were in a “morphologic leukemia-free state.” This still allows stem cell transplants to occur. It even worked with high risk issues.
Decitabine, venetoclax and ponatinib made up the effective combination therapy.
To: Mazey; ckilmer; goodnesswins; Jane Long; BusterDog; jy8z; ProtectOurFreedom; matthew fuller; ...
The “Take Charge Of Your Health” Ping List
This high volume ping list is for health articles and studies which describe something you or your doctor, when informed, may be able to immediately implement for your benefit.
Email me to get on either the “Common/Top Issues” (20 - 25% fewer pings) or “Everything” list.
2 posted on 09/21/2024 3:59:43 PM PDT by ConservativeMind (Trump: Befuddling Democrats, Republicans, and the Media for the benefit of the US and all mankind.)
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.
FreeRepublic.com is powered by software copyright 2000-2008 John Robinson
